Aventis Sees “Blurring” Of Rx/OTC Distinctions; Change Coming For Allegra?
Executive Summary
The antihistamine market can no longer comfortably be divided between prescription and OTC entrants, Aventis Chief Operating Officer Richard Markham suggested during the J.P. Morgan health care conference in San Francisco Jan. 13